REG - N4 Pharma PLC - Result of AGM

N4 PharmaAnnouncement

Yesterday 14:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250630:nRSd0274Pa&default-theme=true

RNS Number : 0274P  N4 Pharma PLC  30 June 2025

 

30 June 2025

 

N4 Pharma plc

 

("N4 Pharma" or the "Company")

Result of AGM

N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary
gene delivery system to enable advanced therapies for cancer and other
diseases, is pleased to announce that at its annual general meeting ("AGM"),
held earlier today, all resolutions were duly passed.

 Resolution                                                       For          For%     Against  Against%  Total        Witheld votes*
 Ordinary Resolution 1                                            30,108,642   99.98%   7,304    0.02%     30,115,946   300,591

 To receive the annual report and audited accounts for the year

 ended 31 December 2024
 Ordinary Resolution 2                                            30,061,328   99.98%   7,304    0.02%     30,068,632   98,809

 To re-elect Luke Cairns as a Director of the Company
 Ordinary Resolution 3                                            30,061,328   99.98%   7,304    0.02%     30,068,632   98,809

 To re-elect Chris Britten as a Director of the Company
 Ordinary Resolution 4                                            30,085,134   99.97%   8,504    0.03%     30,093,638   80,791

 To elect Michael Palfreyman as a Director of the Company
 Ordinary Resolution 5                                            30,078,746   99.97%   8,504    0.03%     30,087,250   80,791

 To elect Alastair Smith as a Director of the Company
 Ordinary Resolution 6                                            30,085,034   99.98%   7,304    0.02%     30,092,338   93,799

 To appoint Gravita Audit II Limited as the Companyʼs auditor

 and to authorise the Directors to determine their remuneration
 Ordinary Resolution 7

 To authorise the Directors to allot shares

                                                                  30,060,137   99.98%   7,304    0.02%     30,067,441   92,193
 Special Resolution 8                                             29,942,019   99.97%   10,004   0.03%     29,952,023   92,393

 To disapply pre-emption rights

 

*Please note a vote withheld is not a vote in law and is not counted in the
calculation of votes validly cast for or against a resolution.

 

- Ends -

 

For more information please contact:

 

 N4 Pharma plc

 Nigel Theobald, CEO                                                       Via N4 Pharma Investor Hub: investors.n4pharma.com

                                                                         (https://investors.n4pharma.com/)
 Luke Cairns, Executive Director

                                                                         https://investors.n4pharma.com/link/5PmqMP
 Submit your questions directly to the management team via the N4 Pharma   (https://investors.n4pharma.com/link/5PmqMP)
 Investor Hub

 SP Angel Corporate Finance LLP                                            Tel: +44 (0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Jen Clarke (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                                     Tel: +44 (0)20 3657 0050

 Joint Broker

 Andy Thacker

 James Pope
 Northstar Communications Limited                                          Tel: +44 (0)113 730 3896

 Investor Relations

 Sarah Hollins

 

About N4 Pharma

N4 Pharma is a pre-clinical biotech company developing Nuvec®, its
proprietary gene delivery system, to enable advanced therapies for cancer and
other diseases.

 

RNA therapeutics are set to impact the treatment of a wide range of diseases
and Nuvec® has several key advantages for RNA gene delivery including the
ability to deliver multiple RNA therapies in a single particle, ease of
manufacturing, protection of the RNA payload to allow for oral delivery, no
unwanted immune response and excellent stability and storage.

 

N4 Pharma is building out its preclinical data set and working towards
first-in-human clinical data to support significant licensing deals for its
Nuvec® platform with gene therapy partners.

 

N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for
IBD which serves as a proof-of-concept programme showcasing all the benefits
of the Nuvec® platform.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at
https://investors.n4pharma.com/auth/signup
(https://investors.n4pharma.com/auth/signup) .

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGBXGDLSBXDGUG